Publications by authors named "David Colnot"

Claim this Profile
M
Mastoid Obliteration Using S53P4 Bioactive Glass Versus Mastoidectomy Alone for Refractory Chronic Suppurative Otitis Media.
Victor J Kroon, David R Colnot, Steven W Mes, Pepijn A Borggreven, Rick van de Langenberg

Otol Neurotol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of S53P4 Bioactive Glass for the Secondary Obliteration of Chronically Discharging Radical Cavities.
Victor J Kroon, Steven W Mes, Pepijn A Borggreven, Rick van de Langenberg, David R Colnot

OTO Open· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cholesteatoma surgery in the pediatric population: remaining challenges in the era of mastoid obliteration.
Victor J Kroon, Steven W Mes, Pepijn A Borggreven, Rick van de Langenberg, David R Colnot

Eur Arch Otorhinolaryngol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mastoid Obliteration Using S53P4 Bioactive Glass in Cholesteatoma Surgery: A 10-Year Single-Center Experience in 173 Adult Patients with Long-Term Magnetic Resonance Imaging Controlled Follow-up.
Victor J Kroon, Steven W Mes, Pepijn A Borggreven, Rick van de Langenberg, David R Colnot

Otol Neurotol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
18F-NaF PET/CT imaging of bone formation induced by bioactive glass S53P4 after mastoid obliteration.
Adriana J Timmermans, Jasper J Quak, Petronella J Hagen, David R Colnot

Eur J Hybrid Imaging· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioactive glass obliteration of the mastoid significantly improves surgical outcome in non-cholesteatomatous chronic otitis media patients.
Joris Vos, Pieter de Vey Mestdagh, David Colnot, Pepijn Borggreven, Claudia Orelio

Eur Arch Otorhinolaryngol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mastoid obliteration with S53P4 bioactive glass in cholesteatoma surgery.
Pieter D de Veij Mestdagh, David R Colnot, Pepijn A Borggreven, Claudia C Orelio, Jasper J Quak

Acta Otolaryngol· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In response to letter to the editor: Lyme disease associated with sudden sensorineural hearing loss: case report and literature review.
Natalie Peeters, David R Colnot

Otol Neurotol· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lyme disease associated with sudden sensorineural hearing loss: case report and literature review.
Natalie Peeters, Brigitta Y M van der Kolk, Steven F T Thijsen, David R Colnot

Otol Neurotol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Hypoxaemia and bradycardia in children during guillotine adenotonsillectomy without intubation].
Maarten J Kretzschmar, Ivar Siccama, Peter L Houweling, Jasper J Quak, David R Colnot

Ned Tijdschr Geneeskd· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical significance of micrometastatic cells detected by E48 (Ly-6D) reverse transcription-polymerase chain reaction in bone marrow of head and neck cancer patients.
David R Colnot, Eline J C Nieuwenhuis, Dirk J Kuik, C René Leemans, Janny Dijkstra

Clin Cancer Res· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma.
Pontus K E Börjesson, Ernst J Postema, Jan C Roos, David R Colnot, Henri A M Marres

Clin Cancer Res· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck.
David R Colnot, Jan C Roos, Remco de Bree, Abraham J Wilhelm, J Alain Kummer

Cancer Immunol Immunother· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reinfusion of unprocessed, granulocyte colony-stimulating factor-stimulated whole blood allows dose escalation of 186Relabeled chimeric monoclonal antibody U36 radioimmunotherapy in a phase I dose escalation study.
David R Colnot, Gert J Ossenkoppele, Jan C Roos, Jasper J Quak, Remco de Bree

Clin Cancer Res· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis